Sunday 18 October 2026
Export BBOT’s income statement to Excel — free account
BridgeBio Oncology Therapeutics, Inc
BBOT Healthcare Biotechnology
In the quarter to June 2026, EPS fell 25.3% and free cash flow fell 88.8%, each against the same quarter a year earlier.
2.82
0.13
−4.41%
Follow BBOT
BridgeBio Oncology Therapeutics, Inc (BBOT) P/E ratio
BridgeBio Oncology Therapeutics, Inc has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FATE Fate Therapeutics, Inc. compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| ACIU AC Immune compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc | n/m |
| IMRX Immuneering Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| QTTB Q32 Bio Inc. compare | 2.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)